Antimicrobial Resistance Surveillance Market Size & Growth Forecast 2027–2036, By Segments (Solution, Application, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Antimicrobial Resistance Surveillance Market size stood at USD 6.82 Billion in 2026 and is predicted to grow at 6.15% CAGR from 2027 to 2036, reaching USD 12.39 Billion by 2036. The industry revenue for 2027 is calculated at USD 7.18 Billion.

• Base Year Value (2026): USD 6.82 Billion
• CAGR (2027-2036): 6.15%
• Forecast Year Value (2036): USD 12.39 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Antimicrobial Resistance Surveillance Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 43.14% in 2026, supported by established healthcare systems, disease surveillance infrastructure, and strong investment in diagnostics and data management.
  • Asia Pacific is growing fastest as infectious disease burdens, healthcare infrastructure, laboratory capabilities, and investment in antimicrobial stewardship and disease monitoring expand.

• Segment Momentum:

  • Diagnostic kits accounted for 45.47% of the market in 2026 because they enable rapid identification of antimicrobial-resistant pathogens, improving treatment decisions, infection control, and surveillance across healthcare settings.
  • Hospitals are the fastest-growing end-use segment, with a 48.44% market share in 2026, driven by increasing demand for resistance monitoring, infection prevention, antimicrobial stewardship, and management of healthcare-associated infections.

• Market Expansion Drivers:

  • Rising antimicrobial resistance burden driving global infectious disease surveillance system expansion
  • Increasing infectious disease prevalence strengthening clinical screening and pathogen monitoring programs
  • AI-enabled diagnostic platforms enhancing early detection and real-time antimicrobial resistance tracking

• Leading Market Participants:

  Prominent companies in the antimicrobial resistance surveillance market include bioMérieux SA (France), Becton, Dickinson and Company (United States), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), Abbott Laboratories (United States), Bruker Corporation (United States), Qiagen N.V. (Germany), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche AG (Switzerland)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 6.82 Billion
  • 2027 Estimated Market Size: USD 7.18 Billion
  • Projected Market Size: USD 12.39 Billion by 2036
  • Growth Forecasts: 6.15% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Diagnostic Kits (Solution) | Clinical Diagnostics (Application) | Hospitals (End-use)
  • Emerging Opportunity Segment: Diagnostic Kits (Solution) | Clinical Diagnostics (Application) | Hospitals (End-use)

Market Growth Drivers and Industry Trends

Rising antimicrobial resistance burden driving global infectious disease surveillance system expansion

The growing challenge of antimicrobial resistance is increasing the need for comprehensive monitoring programs that will drive the antimicrobial resistance surveillance market growth. Healthcare authorities and public health organizations are strengthening surveillance systems to monitor resistance patterns, identify emerging threats, and support evidence-based antimicrobial stewardship strategies. Continuous collection and analysis of microbiological data enable earlier detection of resistance trends, allowing healthcare systems to improve infection control measures and guide more effective clinical decision-making across diverse care settings.

Increasing infectious disease prevalence strengthening clinical screening and pathogen monitoring programs

Rising incidence of infectious diseases is encouraging broader implementation of laboratory screening and pathogen surveillance initiatives, with the antimicrobial resistance surveillance market benefiting from expanding diagnostic and epidemiological monitoring activities. Healthcare providers increasingly rely on systematic surveillance to identify infectious agents, evaluate resistance profiles, and track disease transmission within healthcare facilities and communities. These monitoring programs strengthen public health preparedness by supporting timely clinical interventions, improving outbreak management, and enhancing the effectiveness of infection prevention strategies.

AI-enabled diagnostic platforms enhancing early detection and real-time antimicrobial resistance tracking

The integration of artificial intelligence into diagnostic workflows is transforming infectious disease surveillance and will propel the antimicrobial resistance surveillance market growth through faster analysis of microbiological data. AI-enabled platforms assist laboratories in identifying resistance patterns, interpreting complex datasets, and supporting rapid clinical decision-making with greater consistency and efficiency. Combined with real-time data integration and automated reporting capabilities, these technologies improve surveillance responsiveness while enabling healthcare organizations to monitor evolving antimicrobial resistance trends across regional and national healthcare networks.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising antimicrobial resistance burden driving global infectious disease surveillance system expansion	2.2%	High	North America, Europe	High	Near Term
Increasing infectious disease prevalence strengthening clinical screening and pathogen monitoring programs	2%	High	Asia Pacific, Latin America	High	Near Term
AI-enabled diagnostic platforms enhancing early detection and real-time antimicrobial resistance tracking	1.6%	Moderate	North America, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America accounted for 43.14% of the antimicrobial resistance surveillance market in 2026, supported by established healthcare systems, extensive disease surveillance infrastructure, and strong emphasis on monitoring antimicrobial-resistant infections. Healthcare institutions and public health authorities increasingly rely on surveillance capabilities to identify resistance patterns, support infection prevention, and guide appropriate antimicrobial use. Growing awareness of antimicrobial resistance as a public health challenge, combined with investment in diagnostic and data-management infrastructure, is strengthening demand for sophisticated surveillance solutions across healthcare settings.

Asia Pacific is expected to register the fastest growth, driven by the rising burden of infectious diseases, expanding healthcare infrastructure, and increasing recognition of antimicrobial resistance as a major public health concern. Improvements in laboratory capabilities and disease monitoring systems are enabling broader collection and analysis of resistance data, particularly as healthcare systems seek to strengthen infection control. Greater emphasis on antimicrobial stewardship, public health preparedness, and coordinated disease surveillance is further encouraging investment in technologies that can support timely detection and monitoring of resistant pathogens.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Solution Segment Analysis: Diagnostic Kits (Largest & Fastest-Growing Segment)

The antimicrobial resistance surveillance market was dominated by the diagnostic kits segment, which accounted for the largest and fastest-growing position with a share of 45.47% in 2026. The segment’s growth is driven by the increasing need for rapid and accurate identification of antimicrobial-resistant pathogens to support effective treatment decisions and public health responses. Diagnostic kits enable efficient detection of resistance patterns and improve surveillance capabilities across healthcare settings. Furthermore, growing emphasis on early diagnosis, infection control, and monitoring of emerging resistance trends is strengthening the adoption of advanced diagnostic kit solutions.

Application Segment Analysis: Clinical Diagnostics (Largest & Fastest-Growing Segment)

The clinical diagnostics segment led the antimicrobial resistance surveillance market, accounting for the largest and fastest-growing share of 43.14% in 2026, supported by the increasing requirement for timely detection of antimicrobial resistance in patient care environments. Clinical diagnostics play a critical role in guiding appropriate antibiotic selection and improving treatment outcomes by providing accurate information on pathogen susceptibility. Additionally, the rising burden of infectious diseases and the growing focus on reducing inappropriate antibiotic usage are driving demand for advanced clinical diagnostic solutions.

End-use Segment Analysis: Hospitals (Largest & Fastest-Growing Segment)

The hospitals segment dominated the antimicrobial resistance surveillance market, capturing the largest and fastest-growing share of 48.44% in 2026, due to the extensive need for resistance monitoring within hospital environments. Hospitals are primary centers for diagnosing and managing infectious diseases, making surveillance solutions essential for infection prevention and antimicrobial stewardship programs. Moreover, increasing efforts to improve patient safety, strengthen infection control practices, and manage healthcare-associated infections are supporting the expansion of this segment.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Solution	Diagnostic Kits, Diagnostic Systems, Diagnostic Software, Services	Diagnostic Kits	Diagnostic Kits
Application	Public Health Surveillance, Laboratory Surveillance, Clinical Diagnostics, Others	Clinical Diagnostics	Clinical Diagnostics
End-use	Hospitals, Clinics, Research & Academic Institutes, Others	Hospitals	Hospitals

Competitive Landscape and Market Positioning

Top players in the antimicrobial resistance surveillance market:

1. bioMérieux SA (France)
2. Becton Dickinson and Company (United States)
3. Danaher Corporation (United States)
4. Thermo Fisher Scientific, Inc. (United States)
5. Abbott Laboratories (United States)
6. BrUKer Corporation (United States)
7. Qiagen N.V. (Germany)
8. Siemens Healthineers AG (Germany)
9. F. Hoffmann-La Roche AG (Switzerland)

Market participants are increasingly differentiating themselves through the breadth of surveillance ecosystems they can support rather than through standalone monitoring capabilities. Competitive momentum is shifting toward platforms that integrate laboratory diagnostics, genomic analysis, epidemiological reporting, and public health data into unified intelligence frameworks capable of supporting timely intervention. As healthcare systems demand greater interoperability across institutions, developers are investing in standardized data exchange, automated analytics, and decision-support functionality that reduces reporting complexity. Providers that can continuously adapt surveillance tools to evolving resistance patterns and regulatory expectations are strengthening their position in a market where scientific credibility and operational reliability carry equal competitive weight.

Industry Development/News

Company Name	Date	Key Development
Africa Centres for Disease Control and Prevention (Africa CDC)	Sep-25	The Africa Centres for Disease Control and Prevention, in partnership with the European Centre for Disease Prevention and Control and the Gabonese Ministry of Health, established a national antimicrobial stewardship training framework in Gabon. This strategic capability initiative strengthens regional workforce capacity and operationalizes One Health-based surveillance infrastructures.
Public Health Agency of Sweden	Sep-25	The Public Health Agency of Sweden expanded its international collaborative network, allocating operational resources to support global, regional, and national containment programs. The strategic expansion strengthens data-sharing frameworks and standardizes public health surveillance methodologies.
European Union	Apr-25	The European Union launched a cross-border public health partnership with the Africa Centres for Disease Control and Prevention to deploy enhanced monitoring capabilities across eight African nations, including Mozambique. The investment scales regional diagnostics infrastructure and capacity to trace drug-resistant infections.
Best dos Santos Public Health Laboratory	Apr-25	The Best dos Santos Public Health Laboratory secured designation as a PAHO/WHO Collaborating Centre, transforming its operational footprint into a strategic regional reference center for Barbados. The integration directly scales local and regional capacities to track and respond to drug-resistant pathogens.
Ineos Oxford Institute for Antimicrobial Research (IOI)	Apr-25	The Ineos Oxford Institute for Antimicrobial Research completed the initial phase of its tracking project in Nigeria, integrating localized diagnostics data systems into the primary care chain. The commercialization of these protocols optimized clinical workflows and surveillance accuracy during neonatal infection monitoring.
Kerala Drug Control Department	Jan-24	The Kerala Drug Control Department structurally advanced regulatory oversight by deploying Operation AMRITH. This state-level enforcement initiative integrates targeted testing parameters and strict data collection models to map antibiotic utilization trends and standardize public surveillance protocols.
Thermo Fisher Scientific	Oct-21	Thermo Fisher Scientific commercialized its ASTar System, a rapid antimicrobial susceptibility testing platform providing minimum inhibitory concentration results within six hours. The technology integration enhances operational efficiency in clinical diagnostics and strengthens the company's competitive positioning within the disease surveillance infrastructure sector.
OpGen, Inc.	Jun-20	OpGen, Inc. entered into a strategic collaboration with the New York State Department of Health to design and implement a digital health tracking system across healthcare institutions statewide. The commercial partnership accelerates the clinical tracking and epidemiological management of multi-drug resistant pathogens.